Cumberland Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $10,837 | $11,713 | $10,435 | $9,085 |
Gross Profit | 8,825 | 10,287 | 8,459 | 7,762 |
EBITDA | 413 | 2,734 | 46 | 13 |
EBIT | -619 | 1,417 | -1,735 | -1,388 |
Net Income | -740 | 1,257 | -1,903 | -1,544 |
Net Change In Cash | 10,837 | 11,713 | 10,435 | 9,085 |
Free Cash Flow | 817 | 3,850 | 1,877 | 516 |
Cash | 16,087 | 15,108 | 17,964 | 17,464 |
Basic Shares | 15,274 | 15,259 | 13,971 | 14,052 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $37,867 | $39,552 | $42,010 | $35,985 |
Gross Profit | 31,281 | 33,485 | 32,892 | 27,173 |
EBITDA | 182 | 153 | 332 | -857 |
EBIT | -5,860 | -5,617 | -4,995 | -5,464 |
Net Income | -6,479 | -6,279 | -5,650 | -5,597 |
Net Change In Cash | 37,867 | 39,552 | 42,010 | 35,985 |
Free Cash Flow | -791 | 5,640 | 6,379 | 5,987 |
Cash | 17,964 | 18,321 | 19,757 | 27,040 |
Basic Shares | 14,060 | 14,298 | 14,563 | 14,904 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.02 |
2025-03-31 | $0.08 |
2024-12-31 | -$0.13 |
